HaemaLogiX’s Israeli patent “Kappa Myeloma Antigen Chimeric Receptors and Uses Thereof” was granted in Israel on 2 August 2023.
Read article +HaemaLogix Chief Scientific Officer, Dr. Rosanne Dunn, was invited to present at Cell and Gene Therapy World Asia, held on 14-15 September in Singapore.
Read article +